Intelligent Antibody Discovery

Therapeutic monoclonal antibodies for medicine

Abeome is a privately-held antibody discovery company focused on the high-throughput selection, analysis and synthesis of monoclonal antibodies with a primary objective to develop best-in-class prescription products for the therapeutic antibody market – the fastest growing segment of global drug sales.

Read More »

Recent News

2020-04-03
Molecular Templates Executes Licensing Transaction with Abeome Corporation

Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), and Abeome Corporation, a monoclonal antibody discovery and development company, have entered into a worldwide licensing agreement in which Molecular Templates has licensed a high affinity antibody directed to PD-L1 and […]

2017-04-19
Abeome and CDC to Collaborate on Zika Antibody Discovery

Athens, Georgia, April 19, 2017 – Abeome Corporation announced today that it has signed a Research Collaboration Agreement (RCA) with Centers for Disease Control and Prevention (CDC) for the identification of novel antibodies binding to the Zika virus using Abeome’s proprietary AbeoMouseTM platform. “We are very pleased to collaborate with the CDC using our proprietary antibody […]